NY-FLEXTRADE-SYSTEMS
23.1.2024 14:01:27 CET | Business Wire | Press release
FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems announces a new offering for traders of public equity to plan, manage, and execute equity offerings via their new issue management system, FlexNIMS.
By leveraging this all-in-one solution, global buy-side firms can reduce the time and risk involved with the new issue management process for IPOs, Follow-Ons, and Block Trades by managing the process from the deal evaluation phase, internal interest aggregation and approvals, to compliance checking, and customized individual allocations on deal day. Finally, FlexNIMS can integrate directly with order management systems to book trades all within one user environment.
FlexNIMS provides seamless integration with order management systems, allowing for efficient booking of trades within a single user interface. This comprehensive approach enhances process efficiency and reduces operational risks, directly contributing to our mission of maximizing shareholder value.
Benefits of FlexNIMS include:
- Comprehensive end-to-end ECM workflow for primary market equity deals.
- Calendar-based system encompassing order entry, aggregation, allocation and booking
- Digital order entry and allocation, reducing errors and increasing PM / trader efficiency
- Automatic publication of deal notifications throughout lifecycle of offering
- Sub-allocations according to the user’s internal allocation policy
- Incorporation of internal legal, compliance and oversight policies
- OMS integration to facilitate order booking and finalization
Vijay Kedia, President and CEO at FlexTrade stated: “We are pleased to launch FlexNIMS, the only product of its kind that is seamlessly integrated with a multi-asset EMS, multiple OMS solutions and provides end-to-end automation of Primary Market workflow while reducing risk and connecting all parties in the pre-IPO process. FlexNIMS enables buy-side firms to capture PM interest in equity offerings, aggregate interest across the firm, automate compliance checks, allocation and finally book the trades in their OMSs. The power in this tool derives from the close working relationship and deep insight from our client, Neuberger Berman, and demonstrates our commitment to innovation.”
Rob Arancio, Head of Trading at Neuberger Berman said: “The team at FlexTrade worked to understand the particular needs of our firm. We believe that the technology will benefit our clients as we work more efficiently in pursuit of best pricing and execution. The FlexTrade team has built an end-to-end solution for Equity Capital Markets participation that allows for full straight-through-processing from notification of a deal, right to allocation of shares in the order management system. The system is live on our platform and has successfully completed a number of transactions. “
To learn more about FlexNIMS visit www.flextrade.com or contact sales@flextrade.com.
About FlexTrade
FlexTrade Systems is the global leader in high-performance trading technology, including multi-asset execution and order management systems that span across equities, fixed income, foreign exchange, futures, and options. We’re recognized globally for our innovation, with our flagship product, FlexTRADER® – a pioneering, broker-neutral execution management trading system – leading our suite of transformative solutions.
With a global presence in 45 countries, we work closely with both buy- and sell-side clients. Our team of over 500 dedicated software developers and industry specialists curate powerful, customized trading workflows across multiple asset classes. Our commitment to customer-centric innovation leads to breakthrough solutions that boost trading performance.
About Neuberger Berman
Neuberger Berman, founded in 1939, is a private, independent, employee-owned investment manager. The firm manages a range of strategies—including equity, fixed income, quantitative and multi-asset class, private equity, real estate and hedge funds—on behalf of institutions, advisors and individual investors globally. Neuberger Berman’s investment philosophy is founded on active management, engaged ownership and fundamental research, including industry-leading research into material environmental, social and governance factors. Neuberger Berman is a PRI Leader, a designation awarded to fewer than 1% of investment firms. With offices in 26 countries, the firm’s diverse team has over 2,750 professionals. For nine consecutive years, Neuberger Berman has been named first or second in Pensions & Investments Best Places to Work in Money Management survey (among those with 1,000 employees or more). The firm manages $439 billion in client assets as of September 30, 2023. For more information, please visit our website at www.nb.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123520108/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom